Hong Kong · Delayed Price · Currency is HKD Cloudbreak Pharma Company Description
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases.
The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease.
It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process; CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery; and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema.
The company was founded in 2015 and is headquartered in Irvine, California.
| Country | Cayman Islands |
| Founded | 2015 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 51 |
| CEO | Jinsong Ni |
Contact Details
Address: 8921 Research Drive Irvine, 92618 United States | |
| Website | cloudbreakpharma.com |
Stock Details
| Ticker Symbol | 2592 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jinsong Ni | Chief Executive Officer |
| Ching Chu Chan | Chief Financial Officer |
| Son Van | Chief Operating Officer |